KR101972998B1 - 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법 - Google Patents

염화물 함량이 조절된 아나모렐린 염산염의 제조 방법 Download PDF

Info

Publication number
KR101972998B1
KR101972998B1 KR1020147018116A KR20147018116A KR101972998B1 KR 101972998 B1 KR101972998 B1 KR 101972998B1 KR 1020147018116 A KR1020147018116 A KR 1020147018116A KR 20147018116 A KR20147018116 A KR 20147018116A KR 101972998 B1 KR101972998 B1 KR 101972998B1
Authority
KR
South Korea
Prior art keywords
anamorelin
hydrochloride
composition
acetate
monohydrochloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147018116A
Other languages
English (en)
Korean (ko)
Other versions
KR20150013115A (ko
Inventor
신 이츠 쿠와베
타케히코 야나기마치
히데유키 요시야마
씨몬 파인스
그루트 엘리노어 데
루비오 실비나 가르시아
피터 마니니
Original Assignee
헬신 헬스케어 에스.아.
오노 야꾸힝 고교 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48225135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101972998(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 헬신 헬스케어 에스.아., 오노 야꾸힝 고교 가부시키가이샤 filed Critical 헬신 헬스케어 에스.아.
Publication of KR20150013115A publication Critical patent/KR20150013115A/ko
Application granted granted Critical
Publication of KR101972998B1 publication Critical patent/KR101972998B1/ko
Assigned to 헬신 헬스케어 에스아 reassignment 헬신 헬스케어 에스아 권리지분의 전부이전등록 Assignors: 오노 야꾸힝 고교 가부시키가이샤
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020147018116A 2012-04-20 2013-04-18 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법 Active KR101972998B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636108P 2012-04-20 2012-04-20
US61/636,108 2012-04-20
PCT/US2013/037159 WO2013158874A1 (en) 2012-04-20 2013-04-18 Methods of producing anamorelin hydrochloride having controlled chloride content

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197011485A Division KR102141323B1 (ko) 2012-04-20 2013-04-18 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법

Publications (2)

Publication Number Publication Date
KR20150013115A KR20150013115A (ko) 2015-02-04
KR101972998B1 true KR101972998B1 (ko) 2019-04-29

Family

ID=48225135

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020147018116A Active KR101972998B1 (ko) 2012-04-20 2013-04-18 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법
KR1020197011485A Active KR102141323B1 (ko) 2012-04-20 2013-04-18 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197011485A Active KR102141323B1 (ko) 2012-04-20 2013-04-18 염화물 함량이 조절된 아나모렐린 염산염의 제조 방법

Country Status (48)

Country Link
US (8) US20140018391A1 (https=)
EP (3) EP3517532B1 (https=)
JP (3) JP6109925B2 (https=)
KR (2) KR101972998B1 (https=)
CN (3) CN110041398A (https=)
AP (1) AP2014008013A0 (https=)
AR (1) AR090725A1 (https=)
AU (1) AU2013249197B2 (https=)
BR (1) BR112014025972A8 (https=)
CA (2) CA2869893C (https=)
CL (1) CL2014002817A1 (https=)
CO (1) CO7131356A2 (https=)
CR (1) CR20140530A (https=)
CY (1) CY1120276T1 (https=)
DK (2) DK2838892T3 (https=)
DO (1) DOP2014000235A (https=)
EA (1) EA031581B1 (https=)
EC (1) ECSP14027739A (https=)
ES (2) ES2658862T3 (https=)
GE (2) GEP20186902B (https=)
HK (1) HK1248694A1 (https=)
HR (1) HRP20180316T1 (https=)
HU (2) HUE050865T2 (https=)
IL (1) IL235064B (https=)
JO (1) JO3353B1 (https=)
LT (1) LT2838892T (https=)
MA (1) MA37524B1 (https=)
MD (1) MD4615C1 (https=)
ME (1) ME02966B (https=)
MX (1) MX354793B (https=)
MY (1) MY170068A (https=)
NI (1) NI201400124A (https=)
NO (1) NO2877697T3 (https=)
NZ (1) NZ700833A (https=)
PE (1) PE20150084A1 (https=)
PH (1) PH12014502351B1 (https=)
PL (2) PL3290410T3 (https=)
PT (2) PT2838892T (https=)
PY (1) PY1316881A (https=)
RS (1) RS56869B1 (https=)
SG (2) SG11201406478XA (https=)
SI (2) SI3290410T1 (https=)
TN (1) TN2014000421A1 (https=)
TW (2) TWI677494B (https=)
UA (1) UA116207C2 (https=)
UY (1) UY34753A (https=)
WO (1) WO2013158874A1 (https=)
ZA (1) ZA201408508B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
GEAP201814459A (en) * 2014-09-04 2018-09-10 Helsinn Healthcare Sa Medical treatments based on anamorelin
EP4659747A2 (en) 2015-07-24 2025-12-10 Lumos Pharma, Inc. Salts and prodrugs of 1-methyl-d-tryptophan
CN108239141A (zh) * 2016-12-23 2018-07-03 江苏先声药业有限公司 一种阿拉莫林的制备方法
CN115569120A (zh) * 2019-08-30 2023-01-06 赫尔森保健股份公司 具有改善稳定性的阿拉莫林片剂的生产方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034593A1 (en) * 1999-11-10 2001-05-17 Novo Nordisk A/S Compound with growth hormone releasing properties
WO2010099522A1 (en) * 2009-02-27 2010-09-02 Helsinn Therapeutics (U.S.), Inc. Enhanced migraine treatments based on ghrelin mimetics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005030698A1 (en) * 2003-09-26 2005-04-07 Ranbaxy Laboratories Limited Process for the preparation of voglibose
US7825138B2 (en) 2004-06-29 2010-11-02 Helsinn Therapeutics (U.S.), Inc. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
CA2677813A1 (en) * 2007-02-13 2008-08-21 Helsinn Therapeutics (U.S.), Inc. Method of treating cell proliferative disorders using growth hormone secretagogues
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034593A1 (en) * 1999-11-10 2001-05-17 Novo Nordisk A/S Compound with growth hormone releasing properties
WO2010099522A1 (en) * 2009-02-27 2010-09-02 Helsinn Therapeutics (U.S.), Inc. Enhanced migraine treatments based on ghrelin mimetics

Also Published As

Publication number Publication date
IL235064A0 (en) 2014-12-31
US20160237115A1 (en) 2016-08-18
PH12014502351A1 (en) 2015-01-12
BR112014025972A8 (pt) 2021-06-22
JP6616853B2 (ja) 2019-12-04
EP2838892A1 (en) 2015-02-25
US10300105B2 (en) 2019-05-28
PE20150084A1 (es) 2015-01-23
KR20150013115A (ko) 2015-02-04
US10576122B2 (en) 2020-03-03
US10905737B2 (en) 2021-02-02
AP2014008013A0 (en) 2014-10-31
AU2013249197B2 (en) 2017-04-06
KR102141323B1 (ko) 2020-08-05
HK1202863A1 (en) 2015-10-09
ES2658862T3 (es) 2018-03-12
WO2013158874A1 (en) 2013-10-24
CN110041398A (zh) 2019-07-23
NI201400124A (es) 2015-09-21
SI2838892T1 (en) 2018-05-31
HK1248694A1 (en) 2018-10-19
US20200276259A1 (en) 2020-09-03
TWI589572B (zh) 2017-07-01
US9872883B2 (en) 2018-01-23
MD20140122A2 (ro) 2015-05-31
HUE050865T2 (hu) 2021-01-28
US9981002B2 (en) 2018-05-29
US9956261B2 (en) 2018-05-01
MD4615C1 (ro) 2019-08-31
PH12014502351B1 (en) 2015-01-12
US20160235804A1 (en) 2016-08-18
SG11201406478XA (en) 2014-11-27
BR112014025972A2 (pt) 2017-06-27
US20190000914A1 (en) 2019-01-03
RS56869B1 (sr) 2018-04-30
MX2014012178A (es) 2015-08-05
SG10201608488RA (en) 2016-12-29
MY170068A (en) 2019-07-03
PY1316881A (es) 2016-06-01
US9403867B2 (en) 2016-08-02
EP3517532A1 (en) 2019-07-31
CA2869893A1 (en) 2013-10-24
ECSP14027739A (es) 2015-12-31
JO3353B1 (ar) 2019-03-13
DK3517532T3 (da) 2022-01-03
AR090725A1 (es) 2014-12-03
PL3290410T3 (pl) 2021-01-11
TWI677494B (zh) 2019-11-21
AU2013249197A1 (en) 2014-10-30
DK2838892T3 (en) 2018-03-12
HRP20180316T1 (hr) 2018-04-06
US20190231843A1 (en) 2019-08-01
IL235064B (en) 2019-09-26
NO2877697T3 (https=) 2018-10-13
CA3031652C (en) 2020-10-27
GEAP201813634A (en) 2018-06-25
CN103857669B (zh) 2019-06-28
PT3517532T (pt) 2021-11-08
CA3031652A1 (en) 2013-10-24
UY34753A (es) 2013-11-29
EP3517532B1 (en) 2021-10-13
EP3290410A1 (en) 2018-03-07
JP2018076375A (ja) 2018-05-17
MA37524A1 (fr) 2016-06-30
DOP2014000235A (es) 2015-01-31
HUE035697T2 (en) 2018-05-28
US20140018391A1 (en) 2014-01-16
KR20190044697A (ko) 2019-04-30
JP6284665B2 (ja) 2018-02-28
MX354793B (es) 2018-03-21
ES2820354T3 (es) 2021-04-20
MA37524B1 (fr) 2017-04-28
TN2014000421A1 (en) 2016-03-30
MD4615B1 (ro) 2019-01-31
ZA201408508B (en) 2020-01-29
TW201348224A (zh) 2013-12-01
CR20140530A (es) 2015-03-25
CL2014002817A1 (es) 2015-08-14
TW201722928A (zh) 2017-07-01
JP2015514779A (ja) 2015-05-21
PL2838892T3 (pl) 2018-05-30
CA2869893C (en) 2019-03-05
EP2838892B1 (en) 2017-12-06
NZ700833A (en) 2016-01-29
EA201401151A1 (ru) 2015-06-30
JP2017101082A (ja) 2017-06-08
UA116207C2 (uk) 2018-02-26
US20150072934A1 (en) 2015-03-12
ME02966B (me) 2018-07-20
CY1120276T1 (el) 2019-07-10
EA031581B1 (ru) 2019-01-31
EP3290410B1 (en) 2020-07-01
US20160229889A1 (en) 2016-08-11
PT2838892T (pt) 2018-02-28
CN110041304A (zh) 2019-07-23
SI3290410T1 (sl) 2020-11-30
CO7131356A2 (es) 2014-12-01
LT2838892T (lt) 2018-03-12
GEP20186902B (en) 2018-10-25
CN103857669A (zh) 2014-06-11
JP6109925B2 (ja) 2017-04-05

Similar Documents

Publication Publication Date Title
US10905737B2 (en) Methods of producing anamorelin hydrochloride having controlled chloride content
HK40007836B (en) Methods of producing anamorelin hydrochloride having controlled chloride content
HK40007836A (en) Methods of producing anamorelin hydrochloride having controlled chloride content
HK1202863B (en) Isolated solid form of anamorelin monohydrochloride with low molar ratio of chloride:anamolerin and low content of residual organic solvent

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 8